Structure:澳研究确定一个抗癌“刹车”分子三维结构

2018-12-18 佚名 中国科学报

澳大利亚研究人员近日宣布,他们确认了免疫系统中一个抗癌“刹车”分子CD96的三维结构。这将有利于研发癌症免疫疗法相关的靶向药物,更好地控制肿瘤扩散。


澳大利亚研究人员近日宣布,他们确认了免疫系统中一个抗癌“刹车”分子CD96的三维结构。这将有利于研发癌症免疫疗法相关的靶向药物,更好地控制肿瘤扩散。

主持这项研究的澳大利亚莫纳什大学生物化学与分子生物学研究员理查德·贝里介绍,人体免疫系统“刹车”的作用是防止免疫系统攻击健康组织。很多肿瘤就利用这种机制,在表面释放出特殊生物标记来欺骗人体启动“刹车”机制,从而躲过免疫系统的攻击。

他说:“我们从动物实验得到的结果显示,通过阻止CD96发挥‘刹车’作用,可能比目前其他疗法更有效地阻止肿瘤扩散……CD96阻断疗法在动物实验中表现出对治疗肺癌、前列腺癌和皮肤癌都很有效,并且副作用低。”

研究人员说,相比之前发现的另外两个抗癌“刹车”分子PD-1和CTLA-4,这次确定结构的CD96分子在动物实验中可以更好地作为控制肿瘤扩散的靶点,因此在癌症免疫疗法领域具有重要应用前景。

癌症免疫疗法是利用人体自身免疫功能来搜寻并杀死癌细胞的治疗方法。贝里说,确定该“刹车”分子的三维结构将有利于科研人员研发相关靶向药物。相关论文近日发表在美国生物期刊《结构》上。

原始出处:

Felix A. Deuss, et al.Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155.Structure.Published online: December 6, 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795146, encodeId=ddc51e95146e7, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri May 10 22:53:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734806, encodeId=e1e01e34806e1, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Sun Apr 07 05:53:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355869, encodeId=b3ea35586982, content=澳研究确定一个抗癌分子。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Dec 19 20:13:42 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355806, encodeId=ce24355806a0, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Dec 19 09:09:21 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-05-10 日月
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795146, encodeId=ddc51e95146e7, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri May 10 22:53:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734806, encodeId=e1e01e34806e1, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Sun Apr 07 05:53:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355869, encodeId=b3ea35586982, content=澳研究确定一个抗癌分子。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Dec 19 20:13:42 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355806, encodeId=ce24355806a0, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Dec 19 09:09:21 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1795146, encodeId=ddc51e95146e7, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri May 10 22:53:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734806, encodeId=e1e01e34806e1, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Sun Apr 07 05:53:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355869, encodeId=b3ea35586982, content=澳研究确定一个抗癌分子。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Dec 19 20:13:42 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355806, encodeId=ce24355806a0, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Dec 19 09:09:21 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 jyzxjiangqin

    澳研究确定一个抗癌分子。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1795146, encodeId=ddc51e95146e7, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Fri May 10 22:53:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734806, encodeId=e1e01e34806e1, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Sun Apr 07 05:53:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355869, encodeId=b3ea35586982, content=澳研究确定一个抗癌分子。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Dec 19 20:13:42 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355806, encodeId=ce24355806a0, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Dec 19 09:09:21 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 kafei

    学习了谢谢

    0

相关资讯

Nat Chem:新型技术可在数分钟内产生自组装的抗癌分子

近日,来自英国华威大学的研究人员通过研究开发了一种简单多用途的方法,该方法可以制造一种人工的抗癌分子,来模拟机体天然防御系统的特性,这种抗癌分子的结构类似于机体的多肽结构,可以帮助机体抵御癌症和感染,相关研究刊登于国际杂志Nature Chemistry上。 研究者表示,目前正在实验室测试中证实这种人工抗癌分子可以有效抑制结肠癌;此前研究人员多肽类分子很难大量生产,但是本文中研究人员开发的